Chugai Pharmaceutical Co., Ltd. (CHGCY)
22.51
+0.33
(+1.49%)
USD |
OTCM |
Nov 13, 16:00
Chugai Pharmaceutical Enterprise Value : 68.64B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 68.64B |
| November 12, 2026 | 67.56B |
| November 11, 2026 | 68.22B |
| November 10, 2026 | 68.71B |
| November 09, 2026 | 69.96B |
| November 06, 2026 | 65.58B |
| November 05, 2026 | 67.79B |
| November 04, 2026 | 67.36B |
| November 03, 2026 | 65.39B |
| November 02, 2026 | 65.85B |
| October 30, 2026 | 65.85B |
| October 29, 2026 | 64.17B |
| October 28, 2026 | 63.61B |
| October 27, 2026 | 67.36B |
| October 26, 2026 | 66.27B |
| October 23, 2026 | 65.45B |
| October 22, 2026 | 64.33B |
| October 21, 2026 | 62.10B |
| October 20, 2026 | 61.96B |
| October 19, 2026 | 59.86B |
| October 16, 2026 | 60.25B |
| October 15, 2026 | 60.29B |
| October 14, 2026 | 57.88B |
| October 13, 2026 | 57.82B |
| October 12, 2026 | 57.49B |
| Date | Value |
|---|---|
| October 09, 2026 | 57.62B |
| October 08, 2026 | 57.75B |
| October 07, 2026 | 58.11B |
| October 06, 2026 | 58.02B |
| October 05, 2026 | 58.11B |
| October 02, 2026 | 57.36B |
| October 01, 2026 | 58.18B |
| September 30, 2026 | 58.97B |
| September 29, 2026 | 57.60B |
| September 28, 2026 | 60.26B |
| September 25, 2026 | 63.45B |
| September 24, 2026 | 63.29B |
| September 23, 2026 | 64.84B |
| September 22, 2026 | 65.46B |
| September 21, 2026 | 65.16B |
| September 18, 2026 | 64.93B |
| September 17, 2026 | 64.61B |
| September 16, 2026 | 61.78B |
| September 15, 2026 | 62.57B |
| September 14, 2026 | 62.47B |
| September 11, 2026 | 62.47B |
| September 10, 2026 | 61.68B |
| September 09, 2026 | 62.99B |
| September 08, 2026 | 63.45B |
| September 04, 2026 | 65.23B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 94.93B |
| Daiichi Sankyo Co., Ltd. | 31.74B |
| Eisai Co., Ltd. | 8.931B |
| Santen Pharmaceutical Co., Ltd. | 3.756B |
| Ono Pharmaceutical Co., Ltd. | 6.362B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 901.42M |
| Revenue (Quarterly) | 2.542B |
| Total Expenses (Quarterly) | 1.640B |
| EPS Diluted (Quarterly) | 0.2739 |
| Gross Profit Margin (Quarterly) | 70.58% |
| Profit Margin (Quarterly) | 35.47% |
| Earnings Yield | 4.32% |
| Operating Earnings Yield | 6.04% |
| Normalized Earnings Yield | 4.396 |